0000899243-16-028315.txt : 20160831
0000899243-16-028315.hdr.sgml : 20160831
20160831182542
ACCESSION NUMBER: 0000899243-16-028315
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20160829
FILED AS OF DATE: 20160831
DATE AS OF CHANGE: 20160831
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sagent Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001369786
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1901 NORTH ROSELLE ROAD, SUITE 700
CITY: SCHAUMBURG
STATE: IL
ZIP: 60195
BUSINESS PHONE: 847-908-1604
MAIL ADDRESS:
STREET 1: 1901 NORTH ROSELLE ROAD, SUITE 700
CITY: SCHAUMBURG
STATE: IL
ZIP: 60195
FORMER COMPANY:
FORMER CONFORMED NAME: Sagent Holding Co.
DATE OF NAME CHANGE: 20090529
FORMER COMPANY:
FORMER CONFORMED NAME: NHS PHARMACEUTICALS
DATE OF NAME CHANGE: 20060720
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Singer Jonathon M
CENTRAL INDEX KEY: 0001375536
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35144
FILM NUMBER: 161864197
MAIL ADDRESS:
STREET 1: C/O LANDAUER INC.
STREET 2: 2 SCIENCE ROAD
CITY: GLENWOOD
STATE: IL
ZIP: 60425
FORMER NAME:
FORMER CONFORMED NAME: Jonathon M Singer
DATE OF NAME CHANGE: 20060914
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2016-08-29
1
0001369786
Sagent Pharmaceuticals, Inc.
SGNT
0001375536
Singer Jonathon M
C/O SAGENT PHARMACEUTICALS, INC.
1901 NORTH ROSELLE ROAD, SUITE 700
SCHAUMBURG
IL
60195
0
1
0
0
EVP and CFO
Common Stock
2016-08-29
4
D
0
3665
21.75
D
35063
D
Common Stock
2016-08-29
4
U
0
7857
21.75
D
27206
D
Common Stock
2016-08-29
4
D
0
27206
21.75
D
0
D
Stock Option to Buy
14.61
2016-08-29
4
D
0
34783
7.14
D
2026-02-22
Common Stock
34783
0
D
Stock Option to Buy
20.16
2016-08-29
4
D
0
10638
1.59
D
2024-02-18
Common Stock
10638
0
D
Stock Option to Buy
16.45
2016-08-29
4
D
0
12067
5.30
D
2023-02-21
Common Stock
12067
0
D
Stock Option to Buy
20.10
2016-08-29
4
D
0
55000
1.65
D
2021-09-19
Common Stock
55000
0
D
Pursuant to the Agreement and Plan of Merger by and among Nichi-Iko Pharmaceutical Co. Ltd., Shepard Vision, Inc. and Sagent Pharmaceuticals, Inc. (the "Merger Agreement"), these shares were canceled and converted into the right to receive $21.75 per share in cash, without interest, less any applicable withholding taxes (the "Consideration").
Pursuant to the Merger Agreement, these shares were disposed of in a cash tender offer by Shepard Vision, Inc. to acquire common stock of Sagent Pharmaceuticals, Inc. in exchange for the Consideration.
Pursuant to the Merger Agreement, these restricted shares were canceled and converted into the right to receive the Consideration.
Represents the disposition of options, which provided for vesting in four equal installments beginning February 22, 2017. The options were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $7.14 per share subject to the option. This per share price represents the difference between the applicable exercise price of the option and the Consideration.
Represents the disposition of options, which provided for vesting in four equal installments beginning February 18, 2015. The options were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $1.59 per share subject to the option. This per share price represents the difference between the applicable exercise price of the option and the Consideration.
Represents the disposition of options, which provided for vesting in four equal installments beginning February 21, 2014. The options were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $5.30 per share subject to the option. This per share price represents the difference between the applicable exercise price of the option and the Consideration.
Represents the disposition of options, which provided for vesting in four equal installments beginning September 19, 2012. The options were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $1.65 per share subject to the option. This per share price represents the difference between the applicable exercise price of the option and the Consideration.
/s/ Jonathon M. Singer
2016-08-31